Joel Federbush, MD
Psychiatry · Paramus, NJNPI 1417000332
Payments from drug & device makers
Across 39 payments — averaging $276.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$10K
- Lundbeck LLC$80
- Takeda Pharmaceuticals U.S.A., Inc.$80
- Johnson & Johnson$26
- Ironshore Pharmaceuticals Inc.$26
- Corium, LLC$25
- plus $100 from 6 others
What the payments were for
- Speaking & faculty fees$8,76081%
- Travel & lodging$1,39213%
- Food & beverage$6286%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 13 | $10,444 |
| Lundbeck LLC | 6 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Johnson & Johnson | 2 | $26 |
| Ironshore Pharmaceuticals Inc. | 2 | $26 |
| Corium, LLC | 4 | $25 |
| Supernus Pharmaceuticals, Inc. | 2 | $24 |
| Bausch Health US, LLC | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
| AbbVie | 1 | $13 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SUBLOCADE$7,957
How this compares
$10,780 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 12 | $18,199 |
| BelsomraSuvorexant | 20 | $8,314 |
| Lisdexamfetamine Dimesylate | 19 | $4,735 |
| Paliperidone ErPaliperidone | 24 | $4,115 |
| DepakoteDivalproex Sodium | 12 | $4,100 |
| CelexaCitalopram Hydrobromide | 11 | $3,509 |
| Bupropion XlBupropion Hcl | 100 | $2,759 |
| Alprazolam | 218 | $2,065 |
| Clonazepam | 115 | $1,255 |
| Olanzapine | 95 | $1,098 |
| Quetiapine Fumarate | 65 | $945 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 44 | $763 |
| Zolpidem Tartrate | 62 | $602 |
| Lamotrigine | 36 | $599 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $597 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Paramus
- Aijaz NanjianiParamus$95K
- Yasir AhmadParamus$39K
- Monica DhingraParamus$28K
- Leon RosenbergCherry Hill$6.4M
- Steven GlassClementon$3.9M
- Judith JosephPaterson$3.8M
- Jeffrey ApterPrinceton$1.7M
- Roberta BallCherry Hill$741K
- Marc CantillonLivingston$524K
- Sanjay VarmaPrinceton$479K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.